<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Cetuximab can reverse chemotherapy resistance in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>This study evaluated the efficacy and safety of the combination of docetaxel and cetuximab as a second-line treatment in docetaxel-refractory oesophagogastric <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Patients received docetaxel 30 mg m(-2) on days 1 and 8, every 3 weeks and cetuximab 400 mg m(-2) on day 1, then 250 mg m(-2) weekly </plain></SENT>
<SENT sid="3" pm="."><plain>Biomarker mutation analysis was performed </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: A total of 38 patients were enrolled </plain></SENT>
<SENT sid="5" pm="."><plain>Response rates were PR 6% (95% CI 2-19%), s.d </plain></SENT>
<SENT sid="6" pm="."><plain>43% (95% CI 28-59%) </plain></SENT>
<SENT sid="7" pm="."><plain>Main grade 3/4 toxicities were febrile <z:hpo ids='HP_0001875'>neutropenia</z:hpo>, <z:hpo ids='HP_0002039'>anorexia</z:hpo>, <z:hpo ids='HP_0002018'>nausea</z:hpo>, diarrhoea, <z:hpo ids='HP_0010280'>stomatitis</z:hpo>, and acneiform <z:e sem="disease" ids="C0015230" disease_type="Disease or Syndrome" abbrv="">rash</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>Median progression-free and overall survival were 2.1 and 5.4 months, respectively </plain></SENT>
<SENT sid="9" pm="."><plain>A landmark analysis showed a trend to improved survival times with increased grade of acneiform <z:e sem="disease" ids="C0015230" disease_type="Disease or Syndrome" abbrv="">rash</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>No KRAS, BRAF or PIK3CA mutations were observed </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSION: Cetuximab and docetaxel achieve modest responses rates, but maintain comparable survival times to other salvage regimens with low rates of toxicity </plain></SENT>
</text></document>